Managing Germline Variants of Uncertain Significance in Viet Nam: Evidence-Based Interpretation, Reclassification and Responsible Communication
DIAGNOSTIC SAFETY & RISK MANAGEMENTPATIENT PARTNERSHIP & COMMUNICATION
11/5/202628 min read


Managing Germline Variants of Uncertain Significance in Viet Nam: Evidence-Based Interpretation, Reclassification and Responsible Communication
A patient undergoes genetic testing because several family members have developed a similar medical condition. The test identifies a change in a gene associated with the suspected disorder, but the laboratory cannot determine whether that change contributes to the disease. The report describes it as a variant of uncertain significance.
For the patient, the finding may initially seem like an answer. A genetic change has been identified, a disease-associated gene appears in the report, and the technical information looks precise. Yet the most important question remains unresolved: does this particular variant explain the patient's condition?
Several years later, new evidence may change the interpretation. Research involving other families, improved population data or functional studies may support reclassification of the variant as likely benign. Alternatively, additional evidence may indicate that it is likely pathogenic or pathogenic.
The underlying DNA sequence has not changed. What has changed is the scientific understanding of its relationship to disease.
This is one of the distinctive challenges of genomic diagnosis. A laboratory can accurately identify a genetic variant without having enough evidence to determine its clinical significance. The original result may be analytically correct even when the interpretation remains uncertain or is subsequently revised.
As genetic and genomic testing becomes more widely available, healthcare organizations increasingly encounter findings that cannot be classified definitively. These findings raise questions about laboratory reporting, clinical interpretation, communication with patients and the responsibility to reassess previously reported information.
In June 2026, the American College of Medical Genetics and Genomics (ACMG) published a professional statement addressing the reporting of variants of uncertain significance in germline genetic and genomic testing. The recommendations consider which uncertain findings should be returned, how they should be presented and how laboratories can support appropriate follow-up without encouraging unsupported clinical decisions.
Research published in October 2026 also identified challenges in integrating genetic counseling expertise into healthcare services in Viet Nam, particularly as the availability of genetic testing expands.
For healthcare organizations, managing genetic uncertainty requires more than an accurate sequencing platform or a technically complete laboratory report. It requires reliable methods for evaluating evidence, selecting clinically relevant findings for reporting, recognizing meaningful classification changes and communicating those changes responsibly.
The goal is not to eliminate uncertainty. It is to ensure that uncertain findings are interpreted according to the available evidence, are not mistaken for established diagnoses and can be reconsidered when new knowledge justifies doing so.
Understanding What a Variant of Uncertain Significance Means
Human genetic variation is extensive. Many differences in DNA sequences are common and have no established harmful effect. Others may contribute to inherited disorders, with clinical consequences that depend on the gene, disease mechanism, inheritance pattern and other factors.
Identifying a genetic variant does not, by itself, establish that the variant causes disease.
The widely used 2015 ACMG and Association for Molecular Pathology (AMP) recommendations established a five-tier framework for interpreting sequence variants associated with Mendelian disorders: pathogenic, likely pathogenic, uncertain significance, likely benign and benign.
A variant of uncertain significance (VUS) is a finding for which the available evidence does not justify classification as pathogenic or likely pathogenic, or as benign or likely benign, under the applicable framework.
The designation does not mean that the variant is necessarily harmful. Nor does it mean that the finding has been proven harmless. It indicates that the evidence remains insufficient or conflicting, preventing a more definitive conclusion.
A VUS may be discovered in a patient whose clinical presentation strongly suggests an inherited disorder. Nevertheless, identifying the variant does not automatically establish a molecular diagnosis.
The distinction between variant classification and diagnostic interpretation is particularly important.
A laboratory may identify a VUS in a gene with a well-established relationship to a particular disease. In that situation, the gene-disease relationship may be supported by strong evidence, while the significance of the specific variant remains uncertain.
A different situation arises when a variant is identified in a gene whose relationship to the suspected disease has not been adequately established. Here, uncertainty may exist both about the gene-disease association and about the individual variant.
Inheritance patterns also influence interpretation. A single heterozygous variant in a gene associated exclusively with an autosomal recessive disorder generally has different implications from a variant in a gene associated with autosomal dominant disease. If two variants are identified in a recessive disease-associated gene, additional evidence may be needed to determine whether they occur on different copies of the gene.
These distinctions matter because the presence of a genetic change is only one part of the evidence needed to explain a patient's condition.
A VUS should therefore be neither dismissed automatically nor treated as confirmation of disease. Its significance must be evaluated within the appropriate scientific and clinical context.
How Evidence Supports Variant Classification
Variant classification requires the structured evaluation of different types of scientific evidence.
Depending on the gene and disease being investigated, relevant evidence may include population frequency, predicted or experimentally demonstrated biological effects, observations in affected individuals, inheritance patterns within families, disease-specific mechanisms and previously established classifications.
Each type of evidence has limitations.
A variant may be extremely rare without being pathogenic. Many rare variants do not cause disease, and rarity alone cannot establish causation.
Computational tools may predict that a genetic change affects protein function or splicing, but their predictions need to be interpreted within an appropriate evidence framework. Results from several prediction tools do not necessarily represent independent evidence, particularly when they rely on overlapping datasets or biological assumptions.
Functional studies can be informative when the experimental system accurately reflects the relevant disease mechanism. However, demonstrating an altered biological function does not automatically establish that the variant causes the patient's clinical condition.
Family studies may provide useful information about segregation or whether a variant arose de novo. Their interpretation depends on factors including family structure, penetrance, variable clinical expression and the reliability of the available phenotype information.
The 2015 ACMG/AMP recommendations provide the foundation for structured sequence variant interpretation. Subsequent work by the Clinical Genome Resource (ClinGen) has refined individual evidence criteria and developed gene- and disease-specific specifications.
For constitutional copy-number variants, ACMG and ClinGen published separate technical standards in 2020. Sequence variants and copy-number changes should therefore be evaluated using the appropriate frameworks rather than assuming that identical criteria apply to every type of genetic alteration.
ClinGen Variant Curation Expert Panels provide specialized guidance for selected genes and conditions. Their work can improve consistency by defining how particular evidence criteria should be interpreted and weighted.
An important principle is that pathogenicity classification should follow the available evidence. Although clinical characteristics can contribute evidence under relevant classification rules, differences between individual patients should not justify inconsistent classifications of the same variant in the same gene-disease context without an appropriate evidentiary basis.
Clinical relevance is a related but distinct question.
The same variant may be relevant to the investigation of one patient's symptoms while offering little explanatory value for another patient's reason for testing. This difference does not necessarily mean that the variant itself should receive a different pathogenicity classification.
Laboratories should document the evidence supporting their classifications and, where relevant, explain how the findings relate to the clinical question.
When evidence remains insufficient, maintaining a VUS classification is more scientifically responsible than assigning a definitive interpretation that cannot be justified.
Why Clinical Information Matters to VUS Reporting
Genetic findings are most useful when interpreted in relation to the reason an examination was requested.
Consider two individuals with the same uncertain variant in a gene associated with an inherited disorder. One has clinical features and a family history strongly suggestive of the condition. The other has no relevant symptoms or family history and underwent testing for an unrelated reason.
The available evidence supporting the variant's pathogenicity may be the same, but its relevance to the clinical investigation is different.
This distinction influences which findings deserve attention in the report and whether additional evaluation is likely to provide meaningful information.
Where appropriate, the requesting clinician should provide relevant clinical features, age at onset, family history, previous investigations and the diagnostic question being considered.
These details help the laboratory assess whether the gene is plausibly related to the phenotype and whether an uncertain finding warrants reporting or further review.
A broad test request with limited clinical information can make this process difficult. The laboratory may identify numerous uncertain variants without sufficient information to determine which are relevant.
Reporting every uncertain finding may burden the clinical team with information that does not meaningfully address the original diagnostic question. Conversely, excluding findings too narrowly when the clinical picture is incomplete may overlook potentially important candidates.
The solution is better coordination between the requesting clinician and the laboratory.
For complex cases, multidisciplinary discussion involving appropriately qualified genetics professionals and relevant clinical specialists may help clarify which findings warrant further investigation.
Not every VUS requires formal multidisciplinary review. The need for additional consultation should reflect the complexity of the evidence, the patient's clinical circumstances and the potential consequences of interpretation.
ACMG 2026: Deciding Which VUS Should Be Reported
The ACMG statement published online on June 12, 2026, Points to Consider for the Reporting of Variants of Uncertain Significance in Germline Genetic and Genomic Testing, provides important guidance on a question that laboratories have approached differently for many years: when should an uncertain finding be included in a clinical report?
The statement addresses germline genetic and genomic testing across different technologies and clinical contexts, including multigene panels, chromosomal microarray analysis, exome sequencing and genome sequencing.
Its recommendations concern variants associated with Mendelian disorders. They should not automatically be extended to somatic tumor variants, all genetic risk alleles or every form of molecular testing.
The central recommendation is that VUS reporting should be informed by the clinical indication and the potential value of the information.
For symptomatic individuals undergoing diagnostic genetic testing, ACMG generally recommends reporting VUS relevant to the phenotype prompting the examination.
When a patient has clinical features strongly suggestive of an inherited disorder, an uncertain finding in a relevant gene may provide an opportunity to obtain additional evidence. Family studies, improved clinical information or future scientific developments may eventually clarify its significance.
The report must nevertheless make clear that the variant has not been established as disease-causing.
Reporting practices also depend on the type and breadth of testing. For a focused multigene panel addressing a particular phenotype, reporting VUS may be appropriate even when detailed phenotype information was not supplied, because the test is generally presumed to have been requested for a relevant clinical indication. For broader exome or genome testing, laboratories may need to distinguish potentially relevant findings from variants with limited correlation to the clinical presentation.
For asymptomatic individuals without a relevant family history, ACMG generally recommends against routine reporting of VUS.
This approach applies to several contexts, including unselected population testing for disease risk, secondary or incidental findings, certain newborn sequencing situations without relevant clinical findings and carrier screening performed on a single individual.
In these circumstances, reporting uncertain findings may create confusion, anxiety or unnecessary clinical activity without providing sufficient evidence to support a change in care.
Family history can materially change that assessment.
An asymptomatic individual with a family history strongly suggestive of an inherited condition may have a legitimate reason to receive information about a relevant VUS. The indication for testing should therefore be considered rather than assuming that all asymptomatic testing situations are equivalent.
The statement also discusses selected exceptions in reproductive, prenatal, newborn and pharmacogenomic testing.
For example, reporting a relevant VUS may be considered in certain reproductive carrier-screening situations when a pathogenic or likely pathogenic variant has been identified in the same disease-associated gene in the reproductive partner.
Such exceptions depend on the specific circumstances, supporting evidence, appropriate counseling and informed consent. They should not be interpreted as a general recommendation to report all uncertain variants identified during reproductive or prenatal testing.
Routine cell-free DNA prenatal screening also follows different interpretive considerations and should not be treated as equivalent to diagnostic germline variant analysis.
The ACMG recommendations reflect professional guidance developed within the United States. Their implementation in Viet Nam requires consideration of the testing context, authorized services, available clinical expertise and applicable national regulations.
The underlying principle is valuable across healthcare settings: detecting an uncertain variant does not automatically mean that including it in every clinical report will benefit the patient.
Making the VUS Category More Informative
Not all uncertain variants have the same balance of evidence.
Some variants have findings that lean toward pathogenicity without meeting the criteria for likely pathogenic classification. Others have evidence suggesting a benign interpretation but remain below the threshold for likely benign classification.
The broad VUS category can therefore include variants with different levels and directions of supporting evidence.
The 2026 ACMG statement encourages greater transparency through VUS subclassification, including designations such as VUS-low, VUS-mid and VUS-high.
These subclasses are intended to distinguish variants whose evidence leans toward benignity from those that may deserve greater attention because additional evidence could support a pathogenic classification.
A VUS-high finding may be a reasonable priority for further evidence gathering, particularly when it is relevant to the patient's phenotype. A VUS-low finding may warrant less emphasis in a report when available evidence suggests that it is unlikely to explain the clinical presentation.
The statement strongly recommends that laboratories communicate VUS subclass information and explain its meaning when such classifications are used. It also recognizes that laboratories not yet using subclasses may appropriately wait for more standardized criteria before implementation.
At the time of the statement's publication, the forthcoming Sequence Variant Classification version 4.0 framework was expected to provide more consistent definitions and evidence thresholds for VUS subclasses.
Until a laboratory has implemented clearly defined and appropriately validated criteria, these labels should not be assumed to have identical technical meanings across different organizations.
Most importantly, VUS-high remains a variant of uncertain significance. It is not equivalent to a likely pathogenic or pathogenic finding.
Subclassification can help prioritize further evaluation, but it should not become an unsupported basis for treatment, surveillance or reproductive decisions.
Its value lies in communicating uncertainty more precisely, not making uncertain evidence appear definitive.
Why a VUS Must Not Be Treated as a Confirmed Diagnosis
One of the most consequential risks in genetic testing is allowing an uncertain finding to acquire the practical meaning of a confirmed pathogenic variant.
A report may identify a VUS in a gene associated with a serious inherited condition. The patient may focus on the disease name, while the clinician considers whether the result explains the presenting symptoms.
Without careful explanation, uncertainty can be mistaken for confirmation.
This may lead to unnecessary investigations, anxiety about future disease or unsupported assumptions about the genetic risks faced by relatives.
In more serious circumstances, an uncertain finding could influence decisions about invasive procedures, preventive surgery, reproductive choices or long-term clinical management.
The ACMG/AMP framework emphasizes that VUS should not be used as established pathogenic findings for clinical decision-making.
That does not mean the patient should receive no further care.
A person with concerning symptoms or a strong family history may still require appropriate investigation, surveillance or treatment based on those clinical factors, regardless of the uncertain genetic result.
The distinction is between management justified by the patient's clinical circumstances and management based on an unproven claim that the VUS causes disease.
Family testing requires similar caution.
Testing relatives may sometimes help obtain segregation evidence for variant classification. This is different from predictive cascade testing based on an established familial pathogenic variant.
A VUS should not automatically be used to determine whether healthy relatives have inherited a confirmed disease risk.
The value and limitations of family studies should be assessed by appropriately qualified professionals, considering the individuals involved and the possible implications of the findings.
Variant Reclassification: When Scientific Knowledge Changes
The interpretation of a genetic variant is not necessarily permanent.
New evidence may emerge through clinical observations, studies involving affected families, functional experiments, population databases or improved understanding of gene-disease relationships.
As the evidence changes, a previously uncertain variant may meet the criteria for another classification.
A VUS may be reclassified as likely benign or benign when additional information reduces the likelihood that it contributes to disease. In other circumstances, new evidence may justify reclassification as likely pathogenic or pathogenic.
Reclassification can also involve findings initially considered more definitive.
These changes should not automatically be interpreted as evidence that the original laboratory examination was technically incorrect.
A variant may have been classified appropriately according to the evidence available at the time. A later interpretation can differ because scientific knowledge has advanced.
A study published online on October 7, 2026, in Thyroid provides an illustration.
Fergus and colleagues examined germline RET testing records involving 616,077 individuals tested between 2017 and 2024.
Among 5,516 individuals initially identified with a RET VUS, 1,607 had a variant that was subsequently reclassified. Of those 1,607 individuals, 1,605 had findings reclassified toward benign interpretations.
The study demonstrates that additional evidence can resolve uncertainty for a substantial proportion of initially uncertain findings within a particular testing population.
However, these results concern the RET gene and the specific population and reclassification practices studied. They should not be used to predict the likelihood or direction of VUS reclassification across all genes or healthcare settings.
The researchers also found differences in initial RET VUS frequencies across self-reported demographic groups.
These observations reinforce the importance of representative genetic reference data, but they do not establish the prevalence or reclassification patterns of VUS among Vietnamese patients.
For healthcare organizations, the broader lesson is that genetic interpretation is evidence-dependent. When an important classification changes, there needs to be a reliable process for evaluating whether the new information should be communicated and whether it could affect clinical care.
Reevaluation, Reanalysis and Retesting Are Different Activities
The terms reevaluation, reanalysis and retesting are sometimes used interchangeably, although they describe different activities.
Variant-level reevaluation involves reviewing the evidence for a previously identified variant to determine whether its classification remains appropriate.
The underlying DNA change may be unchanged, while new population information, functional data, segregation findings or clinical observations alter its interpretation.
Case-level reanalysis involves reconsidering the broader genetic or genomic investigation. It may include reviewing previously reported and unreported findings, incorporating new phenotype information, considering newly established gene-disease relationships or applying updated analytical approaches.
A previously nondiagnostic case may yield a new explanation even when no originally reported VUS changes classification.
Retesting involves performing another genetic examination, potentially using improved technology, broader sequencing capabilities or a different analytical method.
The ACMG's 2019 statement on reevaluation and reanalysis, reaffirmed in 2024, provides an established framework for distinguishing these activities.
Which approach is appropriate depends on the clinical question.
A patient whose symptoms have evolved may benefit from case-level reanalysis using the updated phenotype. Another patient may require targeted reevaluation of a particular variant because new scientific evidence has emerged.
In some circumstances, a new genetic test may be more informative than reconsidering the original data.
None of these approaches should be considered automatically necessary for every patient with a VUS. Their potential value should be assessed in relation to the clinical circumstances, available evidence, technical capabilities and resources.
Who Is Responsible When a Classification Changes?
Variant reclassification creates a governance challenge because the laboratory, clinician and patient may no longer have the same relationship they had when the original examination was performed.
A laboratory may identify new evidence several years after issuing a report. The requesting clinician may have left the institution, the patient may now receive care elsewhere, or previously recorded contact information may no longer be current.
Without an agreed process, clinically important information can remain within laboratory records without reaching a professional responsible for assessing its implications.
The ACMG's reevaluation guidance recommends that laboratories establish policies for reviewing relevant evidence and managing updated reports. The 2026 VUS statement also encourages laboratories to update reports when classifications change.
However, these recommendations do not establish one universal requirement for continuous reassessment of every historical variant or guarantee that all patients can be contacted indefinitely.
Reevaluation and reclassification require scientific expertise, reliable information systems and administrative resources. Laboratories differ considerably in their capacity to maintain ongoing monitoring programs.
A practical policy should therefore establish which classification changes receive priority.
Downgrading a previously reported pathogenic or likely pathogenic variant may have substantial clinical implications if earlier decisions relied on that classification.
Similarly, reclassifying a relevant VUS as likely pathogenic or pathogenic may warrant timely professional review because the updated information could affect diagnosis or management.
Reclassification from VUS to likely benign or benign may also be meaningful, particularly when the original uncertain finding had been considered a possible explanation for the patient's condition.
Not every change in evidence strength or classification will have the same consequences.
The laboratory should determine which changes require formal review, an updated report or additional communication according to its professional scope and established policies.
The responsible clinician must then consider the updated interpretation in the context of the patient's circumstances and determine whether further assessment or management is appropriate.
This division of responsibilities helps preserve laboratory accountability while recognizing that clinical decisions require professional judgment.
A laboratory's responsibility to produce and communicate reliable genetic information should not be confused with an obligation to manage every subsequent aspect of patient care.
Prioritizing Reclassification Without Promising Lifelong Monitoring
Continuous reassessment of every previously reported variant would require substantial scientific, technical and administrative resources.
Genetic databases change frequently, new research is published and the number of variants identified through genomic testing continues to increase.
Attempting to review every historical finding whenever new information becomes available may not be feasible or proportionate to the potential clinical benefit.
The ACMG's reevaluation guidance recognizes the value of prioritizing review according to potential clinical impact.
A risk-based approach may focus on changes that could invalidate a previously established genetic diagnosis, newly support an important explanation for a patient's condition or otherwise materially affect management.
Other findings may warrant reassessment when a clinician requests further interpretation or new clinical information becomes available.
An organization may also periodically review selected high-priority variants according to its service scope and available resources.
Such a policy does not necessarily require every VUS to be reviewed at a fixed interval.
Nor should it create an unsupported expectation that a laboratory will automatically notify every previously tested patient whenever scientific knowledge changes.
The scope of ongoing responsibilities depends on applicable law, professional requirements, institutional arrangements and the services provided.
Patients and clinicians should receive appropriate information about whether reevaluation is routinely offered, whether updated reports may be issued and how new clinical questions can be referred for assessment.
These limitations are important because an expectation of indefinite monitoring may not be realistic.
A sustainable approach should concentrate on changes likely to matter clinically while maintaining transparent documentation of how review and communication decisions are made.
Genetic Reports, Traceability and Evidence Resources
A genetic report should allow an appropriately qualified healthcare professional to understand what was identified, how it was classified and what limitations affect the interpretation.
Depending on the method and clinical context, relevant information may include standardized variant nomenclature, the reference sequence or genome assembly, gene name, zygosity, relevant gene-disease association and reported classification.
The report should also explain the applicable classification framework and relevant evidence supporting the interpretation.
When a VUS is reported, uncertainty should be stated clearly. If subclasses are used, their meanings should be explained so that a VUS-high designation is not mistaken for a confirmed pathogenic finding.
The distinction between a well-established disease-associated gene and a candidate gene supported by limited evidence should also be apparent.
Where additional evidence might help resolve uncertainty, the laboratory may identify potentially informative follow-up activities. Such suggestions should be proportionate to the clinical context and should not imply that every uncertain finding requires additional family testing.
Traceability becomes particularly important when classifications change.
A laboratory should be able to identify the original result, the earlier classification, the evidence supporting a revised interpretation and the date on which the change was approved.
Updated reports should be clearly identifiable and appropriately linked to previous reports according to the laboratory's reporting procedures. Earlier interpretations should not be silently overwritten in a way that obscures their history.
Public genetic databases can support this process.
ClinVar, maintained by the U.S. National Center for Biotechnology Information, collects submitted interpretations of genetic variants and related supporting information. ClinGen provides expert resources for evaluating gene-disease relationships and variant pathogenicity.
These resources are valuable, but their classifications should not be copied into clinical reports without appropriate professional review.
ClinVar contains submissions from different laboratories and organizations. Interpretations may differ because submitters used different evidence, classification criteria or update schedules.
Its review-status system helps users understand the level of review associated with submitted interpretations. However, ClinVar does not independently adjudicate every submission or guarantee that every listed classification is correct.
Laboratories should assess the quality, relevance and currency of the available evidence, particularly when conflicting interpretations could influence clinical care.
Responsible data sharing can improve the collective evidence base for rare and uncertain variants. The ACMG encourages laboratories to contribute appropriate variant interpretations to ClinVar and other knowledge-sharing resources, including findings not returned in individual clinical reports.
Such contributions must nevertheless comply with applicable confidentiality, consent and data protection requirements.
The scientific value of sharing variant-level evidence does not automatically authorize unrestricted disclosure of identifiable genetic records or detailed family information.
Communicating Uncertainty to Patients and Families
A genetic report may be scientifically accurate yet difficult for a patient to understand.
Terms such as pathogenic, likely benign and variant of uncertain significance have technical meanings that may not be immediately clear to people receiving their results.
A patient may ask whether the genetic change caused the disease, whether children or siblings could be affected and whether treatment or surveillance should change.
These are reasonable questions, but the answers may remain uncertain.
A responsible explanation should distinguish what the examination established from what it did not establish.
A VUS means that a genetic variant was detected, but the available evidence is insufficient to determine confidently whether it contributes to the relevant disease.
The finding may become more informative in the future, but reclassification is not guaranteed.
Healthcare professionals should avoid describing an uncertain variant as a confirmed inherited diagnosis. Equally, they should not suggest that the entire investigation has no value simply because no definitive molecular explanation was identified.
The absence of a confirmed pathogenic variant does not necessarily exclude an inherited disorder. The testing method may have limitations, some genetic mechanisms may not have been assessed, and scientific understanding of the disease may remain incomplete.
Clinical assessment therefore continues to matter.
Communication should also reflect the patient's circumstances and preferences. Genetic information can influence an individual's understanding of health, family relationships and reproductive decisions.
Some people may want extensive information about uncertain findings. Others may prefer an explanation focused on what the result means for their immediate clinical care.
Appropriate pretest information can help establish realistic expectations about the types of findings that may be reported and the possibility that the result will remain inconclusive.
The 2026 ACMG statement recognizes the importance of patient preferences while acknowledging that highly individualized reporting choices may not be feasible in every routine clinical testing environment.
Where genetic counseling expertise is available, appropriately qualified professionals can help patients and families understand the implications and limitations of their results.
The purpose is not to provide certainty where none exists. It is to help individuals understand the evidence, the remaining uncertainty and the clinical considerations justified independently of an unconfirmed variant.
Genetic Findings and the Rights of Family Members
Germline genetic information may have implications for biological relatives, but those implications require careful interpretation.
A variant may have been inherited from a parent or may also occur in other family members. Family history and segregation information can sometimes help determine whether a finding contributes to disease.
However, identifying a VUS does not mean that relatives have inherited a confirmed genetic disorder.
Nor does it automatically justify predictive testing or major medical decisions based on the uncertain finding.
Family studies may be appropriate when they can provide useful evidence for variant interpretation. Their purpose should be distinguished from cascade testing based on an established pathogenic familial variant.
Genetic information can also reveal sensitive details about biological relationships or family circumstances.
Healthcare organizations should ensure that family-related investigations and communication occur through appropriate professional processes and respect the confidentiality and rights of the individuals involved.
The potential relevance of a genetic finding to relatives does not automatically authorize a laboratory or clinician to disclose the patient's genetic information directly to family members.
Applicable consent, confidentiality and other legal requirements must be considered.
The challenge is to support responsible use of family information without turning uncertain findings into unsupported assumptions about inherited risk.
The Situation in Viet Nam: Genetic Testing and Interpretation Capacity
Genetic and genomic testing is increasingly available in Viet Nam, creating opportunities to investigate inherited diseases and selected hereditary risks more comprehensively.
However, expanding access to testing does not automatically ensure equivalent access to specialized interpretation and genetic counseling.
A qualitative study by Burke and colleagues, published in the Journal of Genetic Counseling in October 2026, examined the needs, challenges and opportunities for integrating genetic counseling expertise into Viet Nam's healthcare system.
The researchers conducted 25 semistructured interviews with healthcare professionals, institutional leaders and genetics specialists representing different settings in Northern, Central and Southern Viet Nam.
Three major themes emerged. Participants described genetic testing as expanding faster than the availability of specialized genetics professionals. They also emphasized the influence of family, spiritual and hierarchical considerations on responses to genetic information, and the need for a phased approach to developing genetic counseling capacity.
The study identified concerns about specialized training, access to appropriate expertise and the communication of complex or uncertain genetic results.
These findings are relevant to VUS management because the clinical value of a genetic report depends partly on whether the receiving professionals and patients can understand its limitations.
Nevertheless, the research was qualitative and involved a purposively selected group of participants. It should not be interpreted as providing nationally representative estimates of genetic counseling availability, VUS reporting errors or the quality of genetic laboratories throughout Viet Nam.
Its value lies in identifying implementation challenges that healthcare organizations can examine within their own services.
For example, facilities can review whether genetic testing requests include adequate phenotype information, whether reports distinguish uncertain findings from confirmed diagnoses and whether clinicians have access to qualified support when complex interpretations arise.
Another important consideration is the representation of Vietnamese and other relevant populations in genetic reference datasets.
Limited population representation may make it more difficult to evaluate the frequency and significance of certain variants. However, the extent of this challenge varies by gene, disease, variant and the other evidence available.
Findings about differences in VUS frequency across demographic groups in international studies should not be assumed to describe Vietnamese patients without appropriate supporting data.
Strengthening interpretation capacity therefore involves more than acquiring sequencing technology. It also requires access to reliable evidence resources, professional training, suitable reporting procedures and effective collaboration between laboratory and clinical teams.
Germline Variant Interpretation Under Viet Nam's Regulatory Framework
Germline genetic testing in Viet Nam operates within the applicable legal framework for medical examination and treatment, laboratory quality management, professional competence, medical records and personal data protection.
The Law on Medical Examination and Treatment No. 15/2023/QH15, as amended and reflected in Consolidated Document No. 26/VBHN-VPQH dated February 26, 2026, provides the broader legal framework governing healthcare services and professional responsibilities.
Healthcare facilities and practitioners must operate within the applicable licensing arrangements, authorized professional activities and technical requirements.
Article 69 establishes provisions concerning medical records, including their creation, updating, preservation, confidentiality and authorized access.
These provisions are relevant to recording genetic examination results and subsequent information that becomes part of the patient's medical record.
They should not, however, be interpreted as establishing a universal obligation to reassess every previously identified VUS at fixed intervals or to notify all patients indefinitely whenever a classification changes.
For laboratory quality management, Circular No. 01/2013/TT-BYT provides an important regulatory reference for medical laboratories at healthcare facilities.
The circular remains relevant as amended, including by Circular No. 25/2026/TT-BYT, issued on June 30, 2026, and effective from August 15, 2026.
The 2026 amendment affecting laboratory quality management concerns participation in external quality assessment arrangements. It should not be presented as creating a comprehensive new national policy on VUS reporting or reclassification.
A more directly relevant technical reference is the Ministry of Health's Decision No. 3287/QD-BYT, issued on October 17, 2025.
The decision promulgated Volume 2 of the professional technical procedures for genetics and molecular biology, comprising 52 procedures. It took effect on July 1, 2026, and provides technical guidance applicable to healthcare facilities performing activities within its scope.
This is an important national reference for the performance of relevant genetic and molecular examinations.
However, the decision should not be described as establishing a comprehensive nationwide VUS governance system equivalent to the ACMG's 2026 recommendations.
A technical procedure governing an examination does not necessarily answer every question about subsequent variant reevaluation, historical report updating or communication with patients years after the original test.
These matters require consideration of applicable professional responsibilities, institutional policies, service arrangements and legal requirements.
ISO 15189:2022 provides an additional international framework for quality and competence in medical laboratories.
Viet Nam's TCVN ISO 15189:2025 is identical to ISO 15189:2022 and replaces TCVN ISO 15189:2014.
These standards are relevant to laboratories developing controlled procedures for genetic interpretation, reporting, personnel competence, documentation and continual improvement.
Nevertheless, international standards and professional statements must be distinguished from legal obligations that apply to particular healthcare facilities under Vietnamese law.
ACMG, AMP and ClinGen guidance may inform professional practice, but their recommendations are not automatically mandatory for every healthcare organization in Viet Nam.
Facilities should determine the requirements applicable to their licensed services and establish procedures consistent with the relevant clinical, technical and legal context.
Protecting Sensitive Genetic Information
Genetic information requires particular care because it may reveal sensitive details about an individual and can also have implications for biological relatives.
Viet Nam's Law on Personal Data Protection No. 91/2025/QH15 and Decree No. 356/2025/ND-CP took effect on January 1, 2026.
Article 4 of the implementing decree identifies health status, biometric data and genetic characteristics among categories of sensitive personal data.
Healthcare organizations processing identifiable genetic information should therefore assess the applicable requirements concerning lawful processing, confidentiality, authorized access, information security and disclosure or transfer of personal data.
Consent requirements, applicable exceptions and other legal conditions must be considered according to the purpose and circumstances of each processing activity.
Genetic information may be used for diagnosis, professional consultation, variant reevaluation, quality improvement or research. These purposes should not automatically be treated as legally interchangeable.
A patient's agreement to undergo genetic testing does not necessarily constitute unrestricted authorization for subsequent research use, international data sharing or disclosure of identifiable genomic information to other organizations.
Where laboratories use external interpretation services, overseas reference laboratories or international genetic databases, they should understand what information is transmitted, who can access it and which data protection or cross-border transfer requirements apply.
De-identification may reduce privacy risks but should not automatically be assumed to eliminate all possibilities of reidentification, particularly when detailed genomic information is involved.
Responsible data governance should enable appropriate scientific collaboration while protecting the rights and confidentiality of patients and families.
Measuring the Quality of VUS Interpretation and Reclassification
Healthcare organizations need ways to evaluate whether their genetic interpretation and reporting processes are reliable.
The proportion of tests producing a VUS may be informative, but it is not a sufficient measure of laboratory quality.
VUS rates vary according to the genes examined, breadth of testing, clinical indications, population representation, classification methods and reporting policies.
A laboratory that reports fewer uncertain variants is not necessarily more accurate. It may use stronger evidence resources, more selective reporting criteria or serve a different testing population.
Similarly, a high reclassification rate is not automatically evidence of superior performance.
Reclassification rates depend on which variants are monitored, how long they have been followed, the availability of new evidence and the laboratory's review practices.
Quality assessment should therefore focus on whether the underlying processes are appropriate and consistently implemented.
Organizations may examine whether relevant classification criteria are documented, whether sufficient clinical information is available for interpretation and whether reports clearly distinguish confirmed findings from uncertainty.
They may also assess whether clinically meaningful classification changes are identified and reviewed according to an established policy.
Where updated reports are issued, the organization can evaluate whether they are accurately linked to previous reports and whether communication responsibilities are clear.
For selected changes with potential consequences for patient management, reviewing the subsequent clinical communication process may provide additional insight.
Such measurements require appropriate definitions and interpretation. A change from VUS to likely pathogenic may deserve different attention from a minor adjustment within a classification category with evidence leaning toward benignity.
Likewise, the absence of reclassification does not necessarily indicate a problem. The evidence may simply remain insufficient.
The purpose of measurement is to support reliable interpretation, transparent reporting and appropriate communication, not to encourage laboratories to assign definitive classifications without adequate scientific support.
Building a Practical VUS Governance Program
Healthcare organizations can strengthen VUS management without creating a comprehensive genomic reanalysis service from the outset.
A practical starting point is to review how uncertain germline findings are currently interpreted, selected for reporting and explained within the organization's authorized services.
The laboratory and relevant clinical teams should establish which classification criteria are used, what clinical information is needed and how reporting policies differ according to the purpose of testing.
The process should distinguish symptomatic diagnostic investigations from testing in asymptomatic individuals and situations involving a relevant family history.
When a VUS is reported, its limitations should be communicated clearly. The report should not imply that the variant has established disease causation or that major clinical decisions are justified by the uncertain finding alone.
The organization should also define how new evidence is identified and how classification changes are evaluated.
Depending on its resources and scope, this may involve reviewing selected high-priority variants, responding to clinician requests, considering credible expert classification updates or reassessing findings when new clinical information becomes available.
The policy should identify who is authorized to approve a revised classification, what circumstances warrant an updated report and how important changes are communicated.
Arrangements are also needed for situations in which the original requesting clinician is no longer available.
The laboratory should have a defined process for determining whether an appropriate alternative authorized recipient can be identified and whether further communication is necessary under the applicable arrangements.
These procedures should not create an unrealistic expectation of indefinite monitoring or transfer responsibility for all subsequent patient care to the laboratory.
Genetic testing personnel, relevant clinicians, quality managers, medical records staff and information technology professionals can contribute according to their responsibilities.
Organizations may begin with a defined genetic testing service or a limited group of variants likely to have meaningful clinical implications.
An initial review may reveal that reports lack adequate clinical context, uncertainty is inconsistently explained or important classification changes are not handled through a clearly documented process.
Improvement can then be evaluated using a manageable set of process measures and selected case reviews.
Patient feedback may also help identify whether explanations are understandable and respectful, although satisfaction alone cannot establish the scientific quality of variant interpretation.
The objective is a sustainable approach that uses evidence responsibly, recognizes uncertainty and supports appropriate clinical decisions without placing unnecessary demands on patients or healthcare professionals.
From Genetic Findings to Reliable Diagnostic Understanding
Germline genetic testing can provide important information about inherited conditions, but not every detected variant has an established clinical meaning.
A laboratory may identify a DNA change accurately while lacking sufficient evidence to determine whether it contributes to disease. That uncertainty may persist or change as scientific knowledge develops.
The 2026 ACMG statement provides important recommendations for deciding which VUS should be reported, communicating differences in the available evidence and supporting appropriate follow-up.
Earlier ACMG guidance on reevaluation and reanalysis reinforces the need to distinguish reassessing a particular variant from revisiting an entire genomic case or conducting a new examination.
Recent research demonstrates that reclassification patterns vary across genes and testing populations. Evidence from Viet Nam also highlights the importance of strengthening access to genetic interpretation expertise and responsible communication as testing becomes more widely available.
For healthcare organizations in Viet Nam, the priority is to establish reliable arrangements connecting genetic findings with appropriate scientific evidence, clinical context and professional responsibility.
That does not mean every VUS must be reported, every uncertain variant must be reassessed periodically or every classification change requires the same response.
It means that uncertainty should be described accurately, clinically consequential changes should receive appropriate attention and responsibilities for reviewing and communicating updated information should be clear.
Diagnostic excellence in genomic medicine is not measured by how many variants a laboratory identifies or how frequently uncertain findings receive definitive classifications. It depends on the reliability of the evidence, the accuracy of its interpretation and the ability to communicate what is known, what remains uncertain and when new information justifies reconsidering an earlier conclusion.
Selected References and Regulatory Sources
Mighton C, Abu-El-Haija A, Aggarwal V, et al. Points to Consider for the Reporting of Variants of Uncertain Significance in Germline Genetic and Genomic Testing: A Statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine. 2026;28(7):102583. Published online June 12, 2026. DOI: 10.1016/j.gim.2026.102583.
Richards S, Aziz N, Bale S, et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine. 2015;17(5):405–424. DOI: 10.1038/gim.2015.30.
Deignan JL, Chung WK, Kearney HM, Monaghan KG, Rehder CW, Chao EC. Points to Consider in the Reevaluation and Reanalysis of Genomic Test Results: A Statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine. 2019;21(6):1267–1270. DOI: 10.1038/s41436-019-0478-1.
American College of Medical Genetics and Genomics. Addendum: Points to Consider in the Reevaluation and Reanalysis of Genomic Test Results. Genetics in Medicine. 2024;26(5):101100. Reaffirmation of the 2019 statement. DOI: 10.1016/j.gim.2024.101100.
Riggs ER, Andersen EF, Cherry AM, et al. Technical Standards for the Interpretation and Reporting of Constitutional Copy-Number Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Clinical Genome Resource. Genetics in Medicine. 2020;22(2):245–257. DOI: 10.1038/s41436-019-0686-8.
Clinical Genome Resource. ClinGen Variant Classification Guidance and Variant Curation Expert Panel Resources.
National Center for Biotechnology Information. ClinVar: Clinical Significance, Review Status and Variant Curation Documentation.
Fergus KB, Richardson ME, Ziv E, Sosa JA, Grubbs EG. RET Variant Reclassification Across Demographic Sub-Groups in a Large-Scale Clinical Population. Thyroid. 2026;36(11):1258–1266. Published online October 7, 2026. DOI: 10.1177/10507256261493762.
Burke MLT, Abad PJB, M'Barek B, et al. Needs, Challenges, and Opportunities for Genetic Counselors in Vietnam: A Qualitative Interview Study With Healthcare Leaders and Genetics Professionals. Journal of Genetic Counseling. 2026;35(5). DOI: 10.1002/jgc4.70303.
International Organization for Standardization. ISO 15189:2022: Medical Laboratories — Requirements for Quality and Competence.
Viet Nam National Standard. TCVN ISO 15189:2025: Medical Laboratories — Requirements for Quality and Competence. Identical to ISO 15189:2022 and replacing TCVN ISO 15189:2014.
Ministry of Health of Viet Nam. Decision No. 3287/QD-BYT, Promulgating Professional Technical Procedures for Genetics and Molecular Biology, Volume 2. October 17, 2025. Effective July 1, 2026.
Ministry of Health of Viet Nam. Circular No. 01/2013/TT-BYT, Guiding the Implementation of Laboratory Quality Management at Medical Examination and Treatment Facilities. January 11, 2013, as amended.
Ministry of Health of Viet Nam. Circular No. 25/2026/TT-BYT, Amending and Supplementing Certain Provisions of Circular No. 01/2013/TT-BYT and Other Ministry of Health Circulars. June 30, 2026. Effective August 15, 2026.
National Assembly of Viet Nam. Law on Medical Examination and Treatment No. 15/2023/QH15, as amended and reflected in Consolidated Document No. 26/VBHN-VPQH dated February 26, 2026.
National Assembly of Viet Nam. Law on Personal Data Protection No. 91/2025/QH15. Effective January 1, 2026.
Government of Viet Nam. Decree No. 356/2025/ND-CP, Detailing Certain Provisions and Measures for Implementing the Law on Personal Data Protection. Effective January 1, 2026.
Professional Scope and Disclaimer
This article is published by Diagnostic Excellence Vietnam (DxEx.vn), a professional initiative dedicated to advancing diagnostic quality, safety and reliability in Viet Nam through evidence-informed knowledge sharing, risk management, measurement and quality improvement.
The content is intended for general professional education and discussion. It does not constitute patient-specific medical or genetic advice, a clinical or laboratory diagnosis, an interpretation or reclassification of an individual genetic variant, a recommendation concerning genetic testing, family testing, reproductive decisions, surveillance, treatment or other clinical management, a determination of professional or technical error, an accreditation assessment or legal advice.
References to ACMG, AMP, ClinGen and other international professional guidance do not imply that these recommendations are automatically mandatory under Vietnamese law. Their applicability depends on the testing context, relevant evidence, professional responsibilities, applicable legal requirements and the circumstances of the healthcare organization and patient.
Decisions concerning genetic test selection, variant interpretation, classification, reporting, reevaluation, reanalysis, communication and patient management must be undertaken by appropriately qualified and authorized professionals in accordance with applicable Vietnamese law, relevant professional standards, validated laboratory procedures and the patient's clinical circumstances.
Diagnostic Excellence Vietnam does not provide genetic testing, individualized genetic counseling, clinical diagnosis or treatment services through this educational publication.
